| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Everolimus |
| Brand | Afinitor® |
| Indication | Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor |
| Assessment Process | |
| Rapid review commissioned | 21/06/2012 |
| Rapid review completed | 12/10/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.